Date | Price Target | Rating | Analyst |
---|---|---|---|
2/15/2024 | $11.00 | Outperform | Wedbush |
1/3/2023 | $18.00 | Equal Weight → Overweight | Wells Fargo |
10/13/2022 | $22.00 | Buy | UBS |
8/15/2022 | $20.00 | Buy | Jefferies |
4/28/2022 | $19.00 | Neutral | Credit Suisse |
2/10/2022 | $19.00 | Equal-Weight | Wells Fargo |
10/14/2021 | $20.00 | Mkt Perform | SVB Leerink |
7/19/2021 | $30.00 | Buy | Guggenheim |
BOSTON, July 08, 2024 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that Markus Warmuth, M.D., Chief Executive Officer, will participate in a fireside chat at the virtual UBS Targeted Protein Degradation Day on Monday, July 15, 2024, at 3:30 p.m. ET. A webcast of the presentation will be accessible via the "Events & Presentations" section of Monte Rosa's website at ir.monterosatx.com, and an archived version will be made available for 30 days following the presentation. About Monte RosaMonte Rosa Therapeutics is a clinical-stage biotechnology company d
Ongoing Phase 1/2 Study of MRT-2359 for MYC-driven solid tumors demonstrates favorable safety and pharmacodynamic profile dosing 0.5 mg using a 21/7 schedule; currently assessing 0.75 mg dose level; final determination of recommended Phase 2 dose and updated clinical results anticipated in H2 2024 IND submission achieved for MRT-6160, a VAV1-directed MGD in development for systemic and neurological autoimmune diseases; initiation of Phase 1 SAD/MAD study expected this summer with Phase 1 clinical data anticipated in Q1 2025 BOSTON, June 27, 2024 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE), a clinical-stage biotechnology company developing novel molecular glue
MRT-6160, a VAV1-directed molecular glue degrader (MGD), inhibits disease progression, pro-inflammatory cytokines and autoantibody production in a model of rheumatoid arthritis Initiation of MRT-6160 Phase 1 SAD/MAD study anticipated in mid-year 2024 with initial clinical data expected in Q1 2025 Poster presentation today at 14:45 CET / 8:45 a.m. ET BOSTON, June 14, 2024 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the company will present preclinical data at the European Alliance of Associations for Rheumatology (EULAR) 2024 Congress, being held J
BOSTON, May 30, 2024 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced three leadership team promotions effective immediately: Sharon Townson, Ph.D., to Chief Scientific Officer; Phil Nickson, Ph.D., J.D., to Chief Business and Legal Officer; and Jennifer Champoux to Chief Operating Officer. "I am very pleased to announce the well-deserved promotions of Sharon, Phil and Jennifer to expanded roles on our leadership team," said Markus Warmuth, M.D., Chief Executive Officer of Monte Rosa Therapeutics. "Each has played a critical role in advancing our pip
Optimal levels of degradation of GSPT1 in peripheral blood mononuclear cells and tumors observed at all doses, consistent with preclinical studies Tumor size reductions observed in patients with biomarker-positive tumors Safety profile supports further clinical development of MRT-2359 Conference call and webcast at 8:00 a.m. ET today BOSTON, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced interim data from the Phase 1 dose escalation part of its ongoing Phase 1/2 open-label, multicenter study of MRT-2359 in patients with MYC-driven solid tumors, including l
Wedbush initiated coverage of Monte Rosa Therapeutics with a rating of Outperform and set a new price target of $11.00
Wells Fargo upgraded Monte Rosa Therapeutics from Equal Weight to Overweight and set a new price target of $18.00
UBS initiated coverage of Monte Rosa Therapeutics with a rating of Buy and set a new price target of $22.00
Jefferies initiated coverage of Monte Rosa Therapeutics with a rating of Buy and set a new price target of $20.00
SC 13D/A - Monte Rosa Therapeutics, Inc. (0001826457) (Subject)
SC 13G/A - Monte Rosa Therapeutics, Inc. (0001826457) (Subject)
SC 13G - Monte Rosa Therapeutics, Inc. (0001826457) (Subject)
SC 13G/A - Monte Rosa Therapeutics, Inc. (0001826457) (Subject)
https://blog.tipranks.com/these-2-strong-buy-penny-stocks-could-jump-at-least-300-says-piper-sandler/
Piper Sandler analyst Edward Tenthoff reiterates Monte Rosa Therapeutics (NASDAQ:GLUE) with a Overweight and maintains $16 price target.
Ongoing Phase 1/2 Study of MRT-2359 for MYC-driven solid tumors demonstrates favorable safety and pharmacodynamic profile dosing 0.5 mg using a 21/7 schedule; currently assessing 0.75 mg dose level; final determination of recommended Phase 2 dose and updated clinical results anticipated in H2 2024. IND submission achieved for MRT-6160, a VAV1-directed MGD in development for systemic and neurological autoimmune diseases; initiation of Phase 1 SAD/MAD study expected this summer with Phase 1 clinical data anticipated in Q1 2025.
MRT-6160, a VAV1-directed molecular glue degrader (MGD), inhibits disease progression, pro-inflammatory cytokines and autoantibody production in a model of rheumatoid arthritis Initiation of MRT-6160 Phase 1 SAD/MAD study anticipated in mid-year 2024 with initial clinical data expected in Q1 2025
4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
8-K - Monte Rosa Therapeutics, Inc. (0001826457) (Filer)
8-K - Monte Rosa Therapeutics, Inc. (0001826457) (Filer)
8-K - Monte Rosa Therapeutics, Inc. (0001826457) (Filer)
8-K - Monte Rosa Therapeutics, Inc. (0001826457) (Filer)
BOSTON, July 26, 2023 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE), a clinical stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the appointment of Anthony M. Manning, Ph.D., to its Board of Directors. Dr. Manning is a highly accomplished drug discovery leader in the field of autoimmune and inflammatory diseases. "Dr. Manning brings extensive knowledge and experience in the field of immunology and inflammation to our Board of Directors, and we're delighted to have him on our team," said Markus Warmuth, M.D., CEO of Monte Rosa. "Tony's experience developing multiple first-in-class therapeutics for the treatment of
BOSTON, March 23, 2023 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE), a clinical stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the appointment of Jan Skvarka, Ph.D., MBA to its Board of Directors. Dr. Skvarka is an accomplished biopharmaceutical executive bringing over three decades of extensive operational, strategic and financial expertise to the Board. "We are delighted to have Dr. Skvarka join our Board of Directors, bringing his extensive experience as a life sciences leader to the team," said Markus Warmuth, M.D., CEO of Monte Rosa. "Having served as the CEO of two clinical-stage companies, Jan has demon
Phase 1/2 clinical trial evaluating MRT-2359 for treatment of MYC-driven solid tumors ongoingDisclosure of initial data from Phase 1 arm of study expected in second half of 2023MRT-2359 received Fast Track designation from FDA for treatment of patients with previously treated, metastatic non-small cell lung cancer (NSCLC) with L-MYC or N-MYC expressionNomination of multiple development candidates anticipated in 2023Year-end 2022 cash balance of approximately $268 million, with cash runway into 2025 BOSTON, March 16, 2023 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE), a clinical stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, to
BOSTON, Dec. 02, 2021 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE), a biotechnology company developing novel molecular glue degrader medicines, today announced the promotion of Jullian Jones, Ph.D., J.D., MBA, to Chief Business Officer. Dr. Jones, who previously served as Senior Vice President, Head of Business Development, has over a decade of experience directing development and partnership transactions within the life sciences industry. "We are delighted to appoint Jullian to the role of Chief Business Officer. In addition to playing a pivotal role in Monte Rosa's upsized $255.6 million IPO earlier this year, Jullian's fingerprints are all over some of the most subst